Darinaparsin

Chemical compound From Wikipedia, the free encyclopedia

Darinaparsin (trade names Darvias and Zinapar) is a drug for the treatment of various types of cancer.[1] It is an arsenic-containing derivative of glutathione.[2]

Trade namesDarvias; Zinapar
Other namesSP-02; ZIO-101; DMAs(III)G
ATC code
Legal status
  • JP:Rx-only
Quick facts Clinical data, Trade names ...
Darinaparsin
Clinical data
Trade namesDarvias; Zinapar
Other namesSP-02; ZIO-101; DMAs(III)G
ATC code
Legal status
Legal status
  • JP:Rx-only
Identifiers
  • (2S)-2-Amino-5-[[(2R)-1-(carboxymethylamino)-3-dimethylarsanylsulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.210.066 Edit this at Wikidata
Chemical and physical data
FormulaC12H22AsN3O6S
Molar mass411.30 g·mol−1
3D model (JSmol)
  • C[As](C)SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N
  • InChI=1S/C12H22AsN3O6S/c1-13(2)23-6-8(11(20)15-5-10(18)19)16-9(17)4-3-7(14)12(21)22/h7-8H,3-6,14H2,1-2H3,(H,15,20)(H,16,17)(H,18,19)(H,21,22)/t7-,8-/m0/s1
  • Key:JGDXFQORBMPJGR-YUMQZZPRSA-N
Close

The mechanism of action of darinaparsin is proposed to involve disruption of mitochondrial function, increased production of reactive oxygen species, and modulation of intracellular signal transduction pathways, thereby inducing cell cycle arrest and apoptosis in cancer cells.[3]

History

Darinaparsin and related compounds were first studied in the 1970s at Texas A&M University. It wasn't until 1998, when a connection between organoarsenic compounds and their potential use in cancer chemotherapy was reported, that interest in darinaparsin as a pharmaceutical drug began.[4] Darinaparsin was licensed to Ziopharm Oncology and then Solasia Pharma for drug development.[4] In 2018, Solasia Pharma licensed darinaparsin to HB Human BioScience SAS of Bogota Colombia.[5] HB Human BioScience SAS began the registration process in Colombia, Peru, Ecuador, Venezuela, Chile, Panama, Costa Rica, and Guatemala, while offering darinaparsin on a compassionate use (expanded access) basis.[5]

Darinaparsin was granted Orphan Drug Designation in the US and Europe as a treatment for peripheral T-cell lymphoma (PTCL).[6]

In Japan, darinaparsin was approved for relapsed or refractory PTCL in June 2022.[7]

Darinaparsin was submitted for INVIMA Approval in Colombia on December 12, 2023.[8]

References

Related Articles

Wikiwand AI